Percheron Therapeutics (ASX:PER) advanced its phase 2b trial investigating the use of avicursen (ATL1102) in patients with Duchenne muscular dystrophy, according to a Monday filing with the Australian bourse.
All 48 patients from the randomized, placebo-controlled trial completed their 25th-week visit, with results expected by the week starting Dec. 16, the filing said. The trial's 12-month study data is anticipated for mid-2025.
The company's shares were down almost 3% in recent Monday trade.
Price (AUD): $0.07, Change: $-0.002, Percent Change: -2.70%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.